240
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion

, &
Pages 1979-1984 | Published online: 11 May 2021
 

Abstract

Purpose

To evaluate the efficacy of topical cyclosporine 0.1% in chondroitin sulfate emulsion for the treatment of dry eye.

Methods

This retrospective multicenter study included 100 eyes of 50 dry eye patients aged ≥18 years, with preoperative ocular surface disease index (OSDI) score >12 or corneal staining grade >1 (in either eye) who underwent dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate emulsion (Klarity-C, ImprimisRx) for 3 months. Postoperative evaluation included comparison of the changes in OSDI score and corneal staining grade after 3 months of treatment from baseline.

Results

From baseline to 3 months, a statistically significant improvement in mean OSDI scores (38.19 vs 24.18, p <0.001) as well as mean corneal staining grade (3.62 vs 2.20, p <0.001) was observed. The proportion of subjects with severe dry eye decreased from 62% to 20% and more than one-third (34%) of patients were in the normal OSDI range. The percentage of eyes with corneal staining grade of 2 or 3 decreased from 21% (baseline) to 8% at 3 months; 50% of the eyes had corneal staining grade of 0. The treatment was found to be safe with no adverse events observed in the study.

Conclusion

Dry eye treatment with twice daily cyclosporine 0.1% in chondroitin sulfate emulsion was found to be safe and effective in reducing signs and symptoms of dry eye.

Acknowledgments

Jan Beiting (Wordsmith Consulting, Cary, North Carolina) and Raman Bedi, MD (IrisARC - Analytics, Research & Consulting, Chandigarh, India) provided research, statistical and editorial assistance in the preparation of this manuscript.

Disclosure

The editorial support was funded by ImprimisRx®, San Diego, CA.

Dr William Trattler reports grants from Imprimis, during the conduct of the study; personal fees from Allergan, grants from Sun, Novartis, Kala, outside the submitted work.

Dr Jennifer Loh reports grants from Imprimis, during the conduct of the study; personal fees from Sun, grants from Allergan, grants from Novartis, grants from Kala, outside the submitted work. None of the authors have any other conflicts of interest to disclose.